The in vitro antiproliferative effects of ICI 195,739, a Sci. 544:310-328, 1988), on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi and some aspects of its mechanism of action are described. Despite previous claims that triazole compounds act on susceptible organisms by essentially the same mechanism demonstrated for the imidazole compounds, i.e., by interfering with the synthesis of ergosterol at the level of the cytochrome P-450-dependent C-14 demethylation of lanosterol, our results indicate that ICI 195,739 acts on T. cruzi epimastigotes by a dual mechanism which involves blockade of ergosterol byosynthesis and a second, still-unidentified target whose alteration leads to immediate growth arrest. Although ICI 195,739 blocks ergosterol biosynthesis at the level of C-14 lanosterol demethylation, as shown by gas-liquid and thin-layer chromatography, growth arrest in ICI 195,739-treated cells is not related to the depletion of the endogenous ergosterol pool, contrary to what was previously found for ketoconazole, the reference compound among antifungal and antiprotozoal azole derivatives. Consistent with this observation is the fact that the concentration of ICI 195,739 required to inhibit de novo synthesis of ergosterol in epimastigotes by 50% is 60 nM, which is essentially identical to that previously found for ketoconazole under identical conditions, while the minimum concentration required to produce complete growth inhibition is 0.1 ,uM, which is 300 times lower than that of ketoconazole. With respect to the intracellular amastigote form proliferating inside vertebrate (Vero) cells, 10 nM is sufficient to eradicate the parasite completely in 96 h, with no effects on the host cells; this concentration is identical to that previously found for ketoconazole. Growth inhibition and morphological alterations induced by ketoconazole can be reversed by exogenously added ergosterol but not by cholesterol; for ICI 195,739, neither sterol is capable of reversing the drug effects. Contrary to what was observed for ketoconazole, the in vitro antiproliferative effects of ICI 195,739 on both forms of the parasite are not potentiated by the simultaneous presence of terbinafine, an allylamine which blocks ergosterol production by the parasite at a different level of the sterol biosynthetic pathway. These results, together with those of an accompanying study of the ultrastructural alterations induced by the drug, strongly support the notion that ICI 195,739 acts on T. cruzi by a novel combination of biochemical and cellular effects, which could explain its extraordinary potency in vivo against the parasite.
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The azole derivatives have proven to be potent antifungal and antiprotozoal compounds which act via specific inhibition of the cytochrome P-450-dependent demethylation of lanosterol, a crucial step in the de novo biosynthesis of ergosterol and related C-24 methylated sterols, which have essential functions in these organisms and cannot be replaced by cholesterol (2, 4-7, 11, 13, 15, 16, 19, 21, 23, 25, 31, 33, 35, 40, 41) . After the initial success of the imidazole derivatives, triazole compounds which display both increased activity and metabolic stability were introduced (26, 32, (36) (37) (38) (39) . In particular, fluconazole and itraconazole have been shown to be potent antiproliferative agents against Leishmania spp. (3, 8, 14) and Trypanosoma (Schizotrypanum) cruzi, the causative agent of Chagas' disease, both in vivo and in vitro (12, 20) .
More recently, ICI 195,739, a novel 3'-styryl-substituted bistriazolyl tertiary alcohol, was developed (1, 9) and shown to have broad antifungal action and particularly high activity * Corresponding author. against T. cruzi when given orally in a murine model system (9, 30) . Initial biochemical studies with fungi (1) have shown that this compound blocks ergosterol biosynthesis at the level of lanosterol demethylation, according to the accepted mechanism of other azole derivatives. However, the extraordinary potency and specificity of this compound against T. cruzi in vivo (30) could indicate particular biochemical targets for the drug or an increased sensitivity of the lanosterol demethylase to the triazole in this organism.
In this report we present the results of a study of the in vivo biological sensitivity of both proliferative stages of the parasite: epimastigotes, which proliferate in the digestive tract of the Reduviid vectors, and amastigotes, which thrive inside vertebrate cells. A biochemical study of the sensitivity of ergosterol biosynthesis of the epimastigote to this drug is also presented. The results, together with those of an accompanying ultrastructural study (18) , suggest that in T. cruzi ICI 195,739 acts via a dual mechanism which involves blockade of ergosterol biosynthesis and a second, as yet unidentified target, whose alteration immediately blocks cell proliferation.
MATERIALS AND METHODS
Both the EP and Y stocks of T. cruzi were used throughout this study. It was found that the susceptibilities of the two stocks to all ergosterol biosynthesis inhibitors tested were indistinguishable in the epimastigote and amastigote forms of the parasite (33) added together with the drug or carrier to the cultures; these were incubated for 48 h, and then the lipids were extracted, fractionated, and analyzed as described above (16) . The radioactive fractions from the thin-layer chromatography were detected by autoradiography with Kodak XRP-5 plates, scraped off, and counted by liquid scintillation spectrometry in a LKB Rack-Beta counter, working at 80% efficiency for 14C. To study the effect of exogenous sterols on the antiproliferative action of the drugs, they were added as Tween 80 suspensions to the growth medium together with the drug exactly as described by Nes et al. (22) . Amastigotes were cultivated in Vero cells maintained in minimal essential medium supplemented with 2% fetal calf serum in a humidified 95% air-5% CO2 atmosphere at 37°C, as previously described (33) . The cells were infected with a 20:1 ratio of tissue culture-derived trypomastigotes to Vero cells for 2 h and then washed three times with phosphatebuffered saline to remove nonadherent parasites; fresh medium with or without the drug was added, and the cells were incubated for various periods of time. The medium was changed every 48 h. Parasite proliferation was quantified by light microscopy as described previously (33) . (9) Lindenmann and H. Stahelin, Sandoz, Ltd., Switzerland, through Luis Rodriguez, Sandoz de Venezuela, S.A. Both drugs were added to the culture medium as dimethyl sulfoxide solutions; the final dimethyl sulfoxide concentration never exceeded 1% (vol/vol), and it had no effect by itself on the proliferation of parasites or on Vero cells. Ketoconazole (15) was provided by John Russe, Janssen Pharmaceutica, Caracas, Venezuela; it was added to the culture medium as aqueous solutions titrated to pH 2.4 with HCl and sterilized by filtration through membrane filters (mean pore size, 0.22 ,um; Millipore Corp., Bedford, Mass.).
RESULTS
The effects of the bis-triazole derivative ICI 195,739 (Fig.  1) on the in vitro proliferation of T. cruzi epimastigotes in liver infusion-tryptose medium are presented in Fig. 2 . The drug significantly slowed the growth of the parasites at concentrations as low as 3 nM and blocked it completely at 0.1 puM, a concentration 300 times lower than those deter- mined previously for ketoconazole and terbinafine (33) . The cells treated with this concentration of ICI 195,739 remained viable for 96 h, but after this period of time morphological alterations and cell lysis began to take place. When we investigated the effects of the combined action of ICI 195,739 and terbinafine on these cells, based on the synergism observed previously between allylamine and ketoconazole under the same conditions (33), some indication of synergism was found at very low concentrations, but at higher concentrations (still below the MICs of both drugs), the effects were at most additive ( Table 1) .
The drug was more effective against the intracellular amastigote form of the parasite proliferating inside Vero cells than against the epimastigotes, as found with other ergosterol biosynthesis inhibitors (33) . The concentration required to reduce the number of infected cells to 50% of the number in the control (untreated) cultures was 1 nM, while the parasites were totally eradicated with ICI 195,739 at 10 nM (Fig. 3) . On the other hand, no effects of the bis-triazole derivative on the proliferation of Vero cells were observed up to 1 ,uM. Again, the combination of ICI 195,739 with terbinafine had only additive effects on the amastigotes (Table 2) , in contrast to the strong synergism observed in the same system with the combination of terbinafine and ketoconazole (33) .
To investigate the basis of these differences, we compared give a final sterol concentration of 10 ,uM had no effect on the proliferation of the epimastigotes by themselves (Fig. 4A) ; however, ergosterol but not cholesterol partially reversed the effect of ketoconazole on the growth rate of the cells and completely abolished the ketoconazole-induced cell lysis observed after 120 h of incubation with the drug, which is caused by alterations in the permeability properties of the cell membrane (34) and massive swelling of the mitochondrion (17) associated with depletion of the preformed ergosterol pool (16) . Direct microscopic observation of the cells (not shown) confirmed that only ergosterol abolished the gross morphological alterations induced by the imidazole derivative, associated with mitochondrial swelling. In contrast, neither of the two sterols had any effect on the growth inhibition and cell lysis induced by ICI 195,739 (Fig. 4B) These results were confirmed qualitatively by thin-layer chromatography (Fig.5B) Methods) and proportionally increased the labeling of the trimethyl sterol fraction, the concentration of the drug required to inhibit incorporation of the precursor into the ergosterol fraction by 50% was 60 nM, which is essentially identical to that found previously for ketoconazole (50 nM [16] ). This concentration is also very similar to that previously reported to inhibit ergosterol biosynthesis by intact Candida albicans cells (38 nM [1] ). Under no conditions was 14C labeling of the cholesterol fraction found, as reported previously (2, 16) .
DISCUSSION
The accepted paradigm for the mechanism of action of antimycotic and antiprotozoal azoles, including both imidazole and triazole derivatives, is the inhibition of cytochrome P-450-dependent demethylation of lanosterol, which in turns lead to cellular alterations due to ergosterol depletion and the accumulation of methylated precursors (2, 4-7, 11, 13, 15, 16, 19, 21, 23, 25, 26, 31-38, 40, 41) ; this mechanism has received direct support by the correlation which has been established between the antiproliferative action of these drugs, their effect on the cell's sterol composition, and their in vitro interaction with the cyotochrome P-450 isoenzymes of susceptible organisms (39) . Supporting evidence for this mechanism in the action of ICI 195,739 on fungi has also been presented previously (1 33 and references therein), the lack of synergism of ICI 195,739 and terbinafine is a further indication that the primary effect of the triazole leading to growth arrest is not related to the ergosterol biosynthesis pathway and is most probably related to the accumulation of a toxic compound.
In support of this hypothesis, an accompanying ultrastructural study (18) revealed that ICI 195,739 at its MIC (0.1 ,uM) induces, immediately after contact with the parasite, the appearance of large electron-dense bodies and many binucleated cells, indicating arrest at cytokinesis. The electrondense bodies could contain the putative toxic compound responsible for the blockade of cytokinesis, but the chemical nature of this compound is still unknown. The same study showed that after 120 h, when the ergosterol content of these cells was partially depleted (Fig. 5) , a large swelling of the mitochondrion was observed, a characteristic effect found in epimastigotes and amastigotes depleted of ergosterol by incubation with ketoconazole (17) , which can be reversed by exogenous addition of the sterol. This shows the second effect of ICI 195,739 on T. cruzi, clearly demonstrating its interference with the ergosterol biosynthesis pathway, which nevertheless is not responsible for primary growth arrest.
In summary, the results of the present in vitro study indicate that the bis-triazole derivative ICI 195,739 acts on T. cruzi by a dual mechanism, which could explain its extraordinary potency in vivo (30) . Further studies on the specific target responsible for the initial growth arrest, as it seems to be specific to the parasite and essential for its proliferation, are in progress.
